Table. 1 Patient characteristics. Source data are provided as a Source Data file
Patient characteristics | No° patients | % | |
|---|---|---|---|
Total | 87 | 100 | |
Sex | Female | 38 | 44 |
Male | 49 | 56 | |
Age at start of immune checkpoint inhibitor [median; IQR] | 64; 56–76 years | ||
Melanoma type | |||
Cutaneous | 67 | 77 | |
Occult | 6 | 7 | |
Uveal | 1 | 1 | |
Acral | 7 | 8 | |
Mucosal | 6 | 7 | |
Adjuvant cohort (Nivolumab/Pembrolizumab) | 22 | ||
Stage I + II/III/IV at initial diagnosis | 10/12/0 | ||
Tumour-free stage III at treatment start | 22 | ||
Patient alive at last follow-up | 19 | ||
Palliative cohort (Ipilimumab + Nivolumab) | 65 | ||
Stage I + II/III/IV at initial diagnosis | 28/22/15 | ||
Unresectable stage IV at start of combined ICI | 65 | ||
First line treatment | 28 | ||
LDH elevated* at start of combined ICI | 34 | ||
S100 elevated** at start of combined ICI | 38 | ||
Patient alive at last follow-up | 29 | ||
